Navigation Links
Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
Date:2/5/2008

SOUTH SAN FRANCISCO, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) will announce financial results for the fourth quarter and year ended 2007 after the markets close on Monday, February 11, 2007 and will hold a webcast teleconference at 4:30 p.m. EDT that day. Members of Anesiva's management team will discuss financial results from the fourth quarter and full year 2007 as well as provide an overview of the company's product pipeline, recent events and milestones.

Interested parties can listen to the live audio webcast by dialing (800) 340-6289 (international dial: (706) 634-1538) or by logging on to http://www.anesiva.com and going to the Investor Information page. For those unable to participate via the Internet, a 24-hour replay will be available for seven days after the call by dialing (800) 642-1687 (international dial: 706-645-9291) and giving the following pass code: 31729950. The webcast will be available until the company's next quarterly financial results conference call.

Anesiva further announced that company management will present at the following events in February 2008:

-- BIO CEO & Investor Conference

Feb. 13, 2008 1:15 p.m. Eastern Time

Presentation:

http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=ANSV&item_id=1 752218

-- Roth Capital Partners 20th Annual Growth Stock Conference

Feb. 21, 2008 9 a.m. Pacific Time

Presentation: http://www.rothcp.com/main/Page.aspx?PageID=7010

Live audio webcasts of the presentations will also be available online via the Investor Relations portion of Anesiva's website at http://www.anesiva.com. Please connect to Anesiva's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Anesiva and its Diverse Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company has one FDA-approved product, Zingo(TM), for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. The second product in Anesiva's pipeline, Adlea(TM), has been shown to reduce pain after only a single administration for weeks to months in multiple settings in numerous mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.


'/>"/>
SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
5. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
6. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Announces Completion of Common Stock Offering
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
11. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... ... September 18, 2017 , ... Transportable biomass conversion ... and torrefied wood is the topic of a September 27 webinar ... economic viability of transportable biomass conversion facilities for producing biochar, briquettes, and torrefied ...
(Date:9/17/2017)... ... September 17, 2017 , ... ... Korean Ministry of Food and Drug Safety (KMFDS) for an Investigational New Drug ... Middle East Respiratory Syndrome coronavirus (MERS-CoV). The study in Korea represents the second ...
(Date:9/14/2017)... ... September 14, 2017 , ... ... portfolio, clinically-relevant starting and ancillary materials that generate unprecedented efficiencies in adult ... therapies. The CliniControl product portfolio will radically simplify major steps in product ...
(Date:9/14/2017)... DC (PRWEB) , ... September 14, 2017 , ... AIM ... IT, Medical Tracking Systems Inc. has won the 2017 Case Study Competition for AIDC. ... technologies which provide benefits that decrease risk” and push the adoption of automated data ...
Breaking Biology Technology:
(Date:3/30/2017)... LOS ANGELES , March 30, 2017  On ... Hack the Genome hackathon at ... This exciting two-day competition will focus on developing health ... experience. Hack the Genome is ... has been tremendous. The world,s largest companies in the ...
(Date:3/30/2017)... Trends, opportunities and forecast in this market ... (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, vein ... use industry (government and law enforcement, commercial and retail, ... others), and by region ( North America ... Pacific , and the Rest of the World) ...
(Date:3/28/2017)... 2017 The report "Video Surveillance ... Servers, Storage Devices), Software (Video Analytics, VMS), and Service ... Forecast to 2022", published by MarketsandMarkets, the market was ... projected to reach USD 75.64 Billion by 2022, at ... base year considered for the study is 2016 and ...
Breaking Biology News(10 mins):